GTC Biotherapeutics (fka GTCB)

[croumagnon]

GTCB's best case valuation models?

I claim some ignorance in that department with respect to GTCB but it will be inetresting if Dew or some of our other knowledgeable posters can give us a run down of what are the expected revenues by GTCB in a best case scenario going forward and what timelines are we expecting in that best case scenario.

It is easy to see that the market for ATryn can justify much higher valuations and then you throw in the rest of the pipeline and GTCB becomes way undervalued. However, I am not clear as to what the share of GTCB will be from these future potential sales Vs their partner's share...